La Myrica cerifera contiene la Myricetina (Dihydromyricetina) che  è un flavonoide presente naturalmente  nelle bacche, frutta, vegetali, erbe, te, e vino rosso. La ricerca ha dimostrato che la  myricetina ha proprietà antiossidanti e antinfammatorie con attività contro i radicali liberi. Può aiutare a ridurre Il colesterolo. La  Myricetina si trova nella corteccia , foglie e radici  della  pianta myrica cerifera. E’ completamente solubile in acqua ed è popolare per the/ infusi.

Gli ingredienti indicati sulla confezione sono : andrographis paniculata pianta (e.s. secco titolato in Andrographoilide 98%), Schizandra chinensis frutti (e.s. titolato in Schizandrina 9%), Myrica cerifera frutti (e.s. titolato in Dihdromyricetina 50%), calcio fosfato, cellulosa microcristallina; antiagglomeranti : magnesio stearato, biossido di silicio.

Prima di assumere qualsiasi cosa è sempre assolutamente indicato rivolgersi al proprio medico curante.

Il prodotto non intende curare alcuna patologia, non va visto come una terapia ma come un integratore.

Bibliografia e studi scientifici

1)Antiviral properties of ent-labdene diterpenes of Andrographis paniculata nees, inhibitors of herpes simplex virus type 1.Wiart C, Kumar K, Yusof MY, Hamimah H, Fauzi ZM, Sulaiman M. Department of Pharmacy, Faculty of Medicine, University of Malaya, Malaysia.

2): Biomed Environ Sci. 2004 Jun;17(2):153-64. Links
Ampelopsin, a small molecule inhibitor of HIV-1 infection targeting HIV entry.Liu DY, Ye JT, Yang WH, Yan J, Zeng CH, Zeng S.
Department of Chemistry, Zhongshan Medical College, Sun Yat-sen University, Guangzhou 510089, Guangdong, China. liudy@gzsums.edu.cn

OBJECTIVE: To investigate the anti-HIV effects of ampelopsin and its interaction with HIV-1 coreceptor CXCR4. METHODS: Through anti-virus experiments in vitro, the inhibitory effect of ampelopsin on HIV-1 infection was verified. Chemotaxis assay was performed to show the ability to induce PBMCs migration by ampelopsin, RANTES and SDF-1alpha. Fluorescence labelling monoclonal antibody was utilized to observe the interaction of ampelopsin and CXCR4. Mice immunosuppressant model was also established to detail the role ampelopsin played in regulating cellular immunological functions. RESULTS: Ampelopsin could protect sensitive cells against HIV-1 infection and dramatically reduce HIV-1 antigen P24 expression. HIV-1SF33 attaching to MT-4 cells was interfered by ampelopsin, and the EC50 was 0.175 mg/mL for cellular protection and 0.024 mg/mL for P24 inhibition. At co-cultivating phase, EC50 was 0.229 mg/mL and 0.197 mg/mL respectively. Furthermore, the EC50 was 0.179 mg/mL and 0.348 mg/mL in acute infection. Human PBMCs migration was induced after being challenged with ampelopsin or chemokines, and synergistic action was observed during co-treatment. Ampelopsin alone resulted in maximal chemotaxis at 1 mg/mL. HIV-1 co-receptor CXCR4 on the surface of PBMCs was decreased by internalization, which indicated the effect of ampelopsin on CXCR4. About 70% CXCR4 was reduced by ampelopsin at 1 mg/mL. Ampelopsin also augmented cellular immunological functions in immunosuppressive mice. CONCLUSION: Ampelopsin displays a strong inhibitive role during HIV-1 absorption, incubation and acute infection. These results are coincident with its immune enhancement.

PMID: 15386941 [PubMed - indexed for MEDLINE]

3) Biofactors. 2004;21(1-4):175-8. Links
Hepatoprotective activity of tocha, the stems and leaves of Ampelopsis grossedentata, and ampelopsin.Murakami T, Miyakoshi M, Araho D, Mizutani K, Kambara T, Ikeda T, Chou WH, Inukai M, Takenaka A, Igarashi K. Research Center, Maruzen Pharmaceuticals Co., Ltd. 1089-8, Sagata, Shin-ichi, Fukuyama-city, Hiroshima 729-3102, Japan.

Hepatoprotective effect of the leaves and stems of Ampelopsis grossedentata together with its main constituent, ampelopsin, were examined on D-galactosamine induced liver injury in rats. The diet containing 50% ethanolic extract (1%) and ampelopsin (0.1%) markedly suppressed the increase of LDH, ALT, AST, alpha-tocopherol levels and GSG/GSSH caused by GalN treatment. These results suggested that ampelopsin from Tocha acted to prevent the oxidative stress in vivo that may have been due to active oxygen species formed by a macrophage by the action of GalN.

PMID: 15630194 [PubMed - indexed for MEDLINE]

4)Zhongguo Zhong Yao Za Zhi. 2003 Dec;28(12):1188-90. Links
[Studies on the effect of dihydromyricetin on antilipid-peroxidation][Article in Chinese]
He GX, Yang WL, Pei G, Zhu YH, Du FL.
College of Food Science and Technology, Hunan Agricultural Univeisity, Changsha 410128, Hunan, China. heguixia@163.net

OBJECTIVE: To study the effects of Dihydromyricetin (DMY) on antilipid-peroxidation. METHOD: The antilipid-peroxidation of DMY on heart, liver, brain tissue homogenate and mitochondria was measured by the determination of malondiadehyde (MDA) induced by Fe2+ -Vit C, Fe2+ -H2O2, Fe-Cys with TBA spectrometric method. RESULT: DMY could inhibit the lipid peroxidation of homogenate and mitochondria. The inhibition exhibited concentration-dependent manner. CONCLUSION: DMY has good antilipid-peroxidation effect, which is worth studing further.

PMID: 15617509 [PubMed - indexed for MEDLINE]

5) Andrographis paniculata: primo studio clinico in persone HIV-positive

Calabrese C, Berman SH, Babish JG, Ma X, Shinto L, Dorr M, Wells K, Wenner CA, Standish LJ. A phase I trial of andrographolide in HIV positive patients and normal volunteers. Phytother Res 2000 Aug;14(5):333-8

Su 13 pazienti HIV-positivi e cinque volontari sani è stato realizzato uno studio clinico di fase I (dose-escalation) utilizzando l'andrografolide estratto dall'Andrographis paniculata. L'obiettivo primario dello studio era di valutare la sicurezza e la tollerabilità del prodotto e, in seconda istanza, di stabilire gli effetti sui livelli plasmatici di HIV1-RNA e sui livelli di linfociti CD4. Nessun partecipante allo studio faceva uso di farmaci antiretrovirali nel corso dello studio. Le persone con alterazioni epatiche o renali erano escluse dallo studio. Gli schemi terapeutici prevedevano 5 mg/kg di peso corporeo per 3 settimane, aumentati a 10 mg/kg per 3 settimane e infine a 20 mg/kg nelle tre settimane finali. Lo studio è stato interrotto dopo 6 settimane a causa degli effetti avversi, compresa una reazione anafilattica in un paziente. Tutti gli effetti avversi si sono comunque risolti entro la fine del periodo di osservazione. Nelle persone HIV+ dopo la somministrazione di 10 mg/kg di andrografolide è stato osservato un significativo aumento dei livelli medi di CD4+ ( da un valore base di 405 cellule/mm3 a 501 cellule/mm3; p =0,002).

Durante lo studio non sono stati registrati cambiamenti statisticamente significativi nei livelli plasmatici medi di HIV1-RNA. Gli autori dello studio concludono sottolineando che l'andrografolide presente in Andrographis paniculata può inibire la sregolazione del ciclo cellulare indotta da HIV, portando ad un innalzamento dei livelli di linfociti CD4 nelle persone sieropositive. Studio realizzato da ricercatori della "Bastyr University Research Institute, Bastyr University", Washington, USA.

6)A phase I trial of andrographolide in HIV positive patients and normal volunteers.

Calabrese C, Berman SH, Babish JG, Ma X, Shinto L, Dorr M, Wells K, Wenner CA, Standish LJ.
Bastyr University Research Institute, Bastyr University, Washington 98028, USA. carlo@bastyr.edu

A phase I dose-escalating clinical trial of andrographolide from Andrographis paniculata was conducted in 13 HIV positive patients and five HIV uninfected, healthy volunteers. The objectives were primarily to assess safety and tolerability and secondarily to assess effects on plasma virion HIV-1 RNA levels and CD4(+) lymphocyte levels. No subjects used antiretroviral medications during the trial. Those with liver or renal abnormalities were excluded. The planned regimen was 5 mg/kg bodyweight for 3 weeks, escalating to 10 mg/kg bodyweight for 3 weeks, and to 20 mg/kg bodyweight for a final 3 weeks. The trial was interrupted at 6 weeks due to adverse events including an anaphylactic reaction in one patient. All adverse events had resolved by the end of observation. A significant rise in the mean CD4(+) lymphocyte level of HIV subjects occurred after administration of 10 mg/kg andrographolide (from a baseline of 405 cells/mm(3) to 501 cells/mm(3); p = 0.002). There were no statistically significant changes in mean plasma HIV-1 RNA levels throughout the trial. Andrographolide may inhibit HIV-induced cell cycle dysregulation, leading to a rise in CD4(+) lymphocyte levels in HIV-1 infected individuals. Copyright 2000 John Wiley & Sons, Ltd.

PMID: 10925397 [PubMed - indexed for MEDLINE] 

7)A new bis-andrographolide ether from Andrographis paniculata nees and evaluation of anti-HIV activity.Reddy VL, Reddy SM, Ravikanth V, Krishnaiah P, Goud TV, Rao TP, Ram TS, Gonnade RG, Bhadbhade M, Venkateswarlu Y. Natural Products Laboratory, Organic Chemistry Division-I, Indian Institute of Chemical Technology, Hyderabad-500 007, India